Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20765052 | 1.00 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BHDAC2 | |
| SCHEMBL20765033 | 0.91 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BHDAC2 | |
| SCHEMBL29889382 | 0.91 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BHDAC2 | |
| SCHEMBL29889767 | 0.91 | ADORA2A (0.45) | ADORA2AADORA1ADORA3ADORA2BPKM | |
| SCHEMBL20765632 | 0.90 | HCRTR1 (0.44) | ADORA2AADORA1ADORA3ADORA2BHCRTR1 | |
| SCHEMBL29889342 | 0.90 | HCRTR1 (0.44) | ADORA2AADORA1ADORA3ADORA2BHCRTR1 | |
| SCHEMBL20765623 | 0.86 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BHCRTR1 | |
| SCHEMBL29889344 | 0.86 | ADORA2A (0.43) | ADORA2AADORA1ADORA3ADORA2BHCRTR1 | |
| SCHEMBL20765100 | 0.86 | ADORA3 (0.43) | ADORA2AADORA1ADORA3ADORA2BHDAC1 | |
| SCHEMBL29889783 | 0.86 | ADORA3 (0.43) | ADORA2AADORA1ADORA3ADORA2BHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.